Lea Felderer
Overview
Explore the profile of Lea Felderer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rehefeldt-Erne S, Nageli M, Winterton N, Felderer L, Weibel L, Hafner J, et al.
Dermatology
. 2016 Apr;
232(3):285-92.
PMID: 27054559
Background: Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin-Goltz syndrome) presents various symptoms and can disfigure patients. The estimated prevalence is around 1:100,000. Objective: To systematically investigate the clinical manifestations of...
2.
Mangana J, Felderer L, Cheng P, French L, Dummer R, Schad K
Ann Dermatol
. 2016 Jan;
27(6):780-1.
PMID: 26719658
No abstract available.
3.
Otsuka A, Dreier J, Cheng P, Nageli M, Lehmann H, Felderer L, et al.
Clin Cancer Res
. 2015 Jan;
21(6):1289-97.
PMID: 25593302
Purpose: Basal cell carcinomas (BCCs) are tumors ignored by immune surveillance. Activated Hedgehog (Hh) signaling within primary cilia is a key driver in the pathogenesis of BCCs. We examined immune...
4.
Dreier J, Dummer R, Felderer L, Nageli M, Gobbi S, Kunstfeld R
Expert Opin Emerg Drugs
. 2014 Apr;
19(3):353-65.
PMID: 24773312
Introduction: Basal cell carcinoma (BCC) is a malignancy that is driven by an activated Hedgehog (Hh) pathway. Smoothened inhibitors are a new promising treatment option for patients with locally advanced...
5.
Dummer R, Goldinger S, Turtschi C, Eggmann N, Michielin O, Mitchell L, et al.
Eur J Cancer
. 2013 Dec;
50(3):611-21.
PMID: 24295639
Background & Aim: Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain...
6.
Dreier J, Felderer L, Barysch M, Rozati S, Dummer R
Expert Opin Pharmacother
. 2013 May;
14(10):1307-18.
PMID: 23656611
Introduction: Basal cell carcinoma (BCC) is the most frequent cancer with increasing incidence over the last decades. Standard of care is surgical excision, upon which complete tumour clearance is achieved...